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Aims of this thesis 
 
 
Neutrophil degranulation, angiogenesis and wound healing are three important 
host responses during inflammation. In this thesis we wanted to study how the 
immunocalin α1-acid glycoprotein (AGP), in its role of immunomodulatory acute 
phase protein, affected this processes in order to help get a better overall 
comprehension of the acute phase reaction. To do so we studied bovine neutrophil 
degranulation within the frame of acute inflammation and, on the lack of a good 
bovine endothelial model, we studied angiogenesis and wound healing on 
endothelial human primary cells. 
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Acute Phase Proteins and the Bovine Mammary Gland 
 
During mastitis the bovine mammary gland produces a bunch of proteins to 
defend itself from a bacterial attack or injury. The so called acute phase proteins 
(APP). These proteins exhort several immunological functions: 
 
• Opsonization 
• Recruitment of immunological cells (neutrophils and monocytes) 
• Induction of metaloproteases (MPP) to degrade the extracellular matrix 
• Complement activation 
• Inhibition of the coagulation 
• Iron binding 
• Hemoglobin binding 
 
Its production and action needs to be tightly regulated to minimize and dampen 
the side effects of inflammation. When the local production of APP is not 
sufficient to contain or eradicate the infection (local response), the liver gets in 
action, producing a much more efficient systemic response (Rainard 2005). 
 
The bovine mammary gland during its local response produces different APP and 
other immune-related factors with diverse activities all of them focused on 
fighting against the invading bacteria (Rainard&Riollet 2006). 
 
The lipopolysaccharide-binding protein (LBP) is one of them, its classic 
function is to bind LPS, to present it to CD14 cells and activate the toll like 
receptor 4 (TLR4) pathway (Zweigner 2006) though now we know that it also 
recognizes other pathogen associated molecular patterns (PAMP’s) a group of 
cytoplasmatic molecules anchored to the membrane of Gram-positive bacteria and 
activating the TLR2 pathway, making of LBP a crucial APP since it can amplify 
the immune response against both classes of bacteria (Rahman 2010). Plasma 
levels can increase up to seven fold during experimental infection with 
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Mannheimia haemolytica (Pasteurella) (Schroedl 2001), and both plasma and milk 
levels do increase during experimental mastitis (Bannerman 2003).  
It is mainly synthesized by the hepatocytes but extra hepatic expression has been 
reported (Rahman 2010) in several  bovine tissues with different intensity and 
distribution: 
 
 
Tissue Intensity Distribution 
Lung Low Multifocal 
Mammary gland High Diffuse 
Parenchyma High Diffuse 
Cistern Moderate Diffuse 
Teat High Diffuse 
Extra hepatic expression of LBP in bovine tissues in physiological conditions (Modified from 
Rahman 2010) 
 
 
Serum Amyloid A3 (SAA3) is one of the major reactants during the acute 
inflammation response (Molenaar 2009). It can increase up to 1000-fold in human 
and mice whereas it’s levels in bovine milk can rise up to 110µg/ml during 
mastitis (Eckersall 2001). As with many other APP it’s exact role it not yet fully 
understood but it’s multifunctional and might include several immunological 
functions (Jensen&Whitehead 1998). 
In humans different SAA’s mRNA’s have been detected in different tissues 
including intestine, pancreas and breast epithelial cells (Urieli-Shoval 1998). In 
the bovine mammary gland it was found at low levels in epithelium with lactation 
phenotype but at high levels in ductal epithelial cells and vesicle engorged alveoli 
(Moleenaar 1996) and strongly induced during mastitis in secretory mammary 
epithelial cells (MEC). With the exception of the liver SAA3 expression profile 
during different physiological states it’s very similar to that found for lactoferrin 
(Molenaar 1996) being more expressed during pregnancy, involution and 
infection than during lactation. 
 
Bovine milk contains very little Lactoferrin (Lf) 20-200ug/ml compared with 
human mil 1-2mg/ml (Rainard 2006). The main source of Lf in bovine milk are 
the mammary epithelial cells (MEC), and while it’s expression it’s moderate/high 
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in the ducts an cisterns it’s totally absent in the proximal end of the teat canal 
(Molenaar 1996). Main function of Lf is bacteriostasis through its iron-chelating 
properties, E.Coli being the  most susceptible to its action among the mastitis-
causing bacteria since it has high iron requirements. These iron-binding properties 
are probably of low efficiency during lactation but likely to be significant when 
the mammary gland is fully involuted (Rainard 2006). Lf also activates the 
classical complement pathway resulting in opsonization of the bacteria as it has 
been shown in S.agalactiae (Rainard 1993). It also seems to have an overall 
dampening action during the acute mastitis by  binding to LPS 
(lipopolysaccharide a constituent of gram-negative bacteria), LTA (lipoteichoic 
acid a major constituent of gram-positive bacteria) and CpG (Rainard 2006). 
 
Haptoglobin (Hp) is also mainly secreted by liver, it is a major APP in ruminants 
(Hiss 2004) and has been suggested and used as a diagnostic marker for mastitis 
(Eckersall 2001) and respiratory diseases in cattle (Heegaard 2000). The use of 
milk Hp as an early marker for mastitis does not work due to the low detection 
limit of the assay (Hiss 2004) but the fact that Hp can be found in milk during 
experimental LPS provoked mastitis even before it increases its serum 
concentration demonstrates the fact that mammary gland synthesizes its own local 
Hp which might be used for its bacteriostatic properties (Eaton 1982, Hiss 2004) 
its down regulation of the immune response by suppressing production of 
proinflammatory cytokines in monocytes, or its capacity to inhibit the respiratory 
burst activity in neutrophils. 
 
α1-Acid glycoprotein (AGP, Orosomucoid) is a minor acute phase protein in 
cattle (Tamura 1989) where it can rise up to 3 fold during acute phase 
inflammation rising from physiological levels (0.3mg/ml) to acute phase levels 
(0.9mg/ml) it is mainly produced by liver but hextrahepatic expression has been 
widely reported in other human tissues such as stimulated alveolar macrophages 
(Fournier 1999), breast epithelial cells (Gendler 1982) or endothelial cells 
(Sorensson 1999) as well as in several bovine tissues (Lecchi 2010) like spleen, 
sub-mandibular gland, lung, uterus and pancreas with of course a higher mRNA 
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expression found in liver, and in at a much lower level in other tissues as lymph 
node, parotid gland, tongue or kidney. In all of them the immunohistochemistry 
revealed endothelial expression,  except for liver where AGP was found all over 
the  cytoplasm. In the mammary gland AGP was found in the epithelium 
(Ceciliani 2005) where it probably has an important role dampening the collateral 
effects of the acute inflammation during mastitis that are often responsible for 
sever lesions to the mammary epithelium (Burvenich 2003). As is Hp and SAA, 
AGP is also present in milk during mastitis where it can be found in two forms a 
low MW (44kDa) isoform that is expressed by the mammary gland epithelium 
(Ceciliani 2007) and a much less abundant high MW one (55-70kDa) produced by 
somatic cells (SC), that considerably rises its concentration during mastitis when 
large amounts of polymorphonuclear cells (PMNC) pass thorough the hemato-
mammary barrier to get to the local site of inflammation and release its granules. 
This high MW AGP  is apparently identical to the isoform found in PMNC which 
in humans has been reported to be expressed during the mieloproliferative phase 
and then carried to the inflammation focus by the mature PMNC (Theilgaard-
Monch 2005). This uncontrolled influx of activated PMNC to the mammary gland 
is considered to be the major cause of damage to the mammary gland during 
mastitis (Ceciliani 2007) the release of the SC-AGP at the local inflammation spot 
where it exhorts all it’s anti-inflammatory activities, including dampening of the 
inflammation and increasing the bacterial resistance is a very important process 
that still needs to be fully understood. 
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The α1-acid glycoprotein (AGP) 
 
α1-acid glycoprotein (AGP), also known as orosomucoid (ORM) was first 
described by Karl Schmid and Richard J.Winzler in 1950 (Schmid 1950, Weimer 
1950). It is one of the major positive acute phase protein (APP)s in the human 
body (Fournier 2000) and in several different species (Ceciliani 2007). 
Throughout  evolution, AGP has been highly conserved, and is basally expressed 
over the life span, even in the face of severe starvation (Liao 1985). Although 
many important biological activities have been attributed to AGP, its exact 
physiological  function(s)  remains unclear. AGP is found in plasma under 
physiological conditions; its concentration in the serum/plasma can increase 
several fold during the acute phase response. 
  
 concentration in plasma 
(mg/ml) 
Increase during acute 
phase reaction 
Human 0.5-1 I 
Bovine 0.2-0.45 I 
Pig 0.3-0.56 O/I 
Dog 0.05-0.8 I 
Cat 0.1-0.48 I 
Mouse 0.2-0.4 I 
Rat 0.1-0.2 II 
 
AGP PLASMA LEVELS IN MULTIPLE SPECIES.O:no change, I:1-10-fold increase, II: >10 
fold increase.  (Ceciliani 2007). 
 
AGP has very unusual biochemical characteristics. It has a molecular weight of 
41-43kDa, with a high carbohydrate content of 45% (Fournier 2000,Schmid 
1977). This molecule has an extremely low pI of 2.8-3.8 and an unusually high 
solubility in both H2O and in polar organic solvents (Fournier 2000). 
Amino Acid Core of AGP 
AGP is encoded by 3 adjacent genes in chromosome 9. The predominant gene 
product, AGP-A (ORM1) is upregulated during the acute phase response, encodes 
a 201 amino acid (aa) precursor protein with a secretory NH2-terminal signal 
peptide of 18 residues (Schmid 1973, Herve  1998, Schonfeld 2008).  
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AMINO ACID SEQUENCE FOR AGP IN MULTIPLE SPECIES 
MOUSE           MALHTVLIILSLLPMLEAQNPEHANFTIGEPITNETLSWLSDKWFFMGAAFRKLEYRQAI 60 
RAT             MALHMVLVVLSLLPLLEAQNPEPANITLGIPITNETLKWLSDKWFYMGAAFRDPVFKQAV 60 
HUMAN           MALSWVLTVLSLLPLLEAQIPLCANLVPVP-ITNATLDQITGKWFYIASAFRNEEYNKSV 59 
BOVINE          MALLWALAVLSLLPLLDAQSPECANLMTVAPITNATMDLLSGKWFYIGSAFRNPEYNKSA 60 
                ***  .* :*****:*:** *  **:     *** *:. ::.***::.:***.  :.::  
 
MOUSE           QTMQSEFFYLTTNLINDTIELRESQTIGDQCVYNSTHLGFQRENGTFSKYEGGVETFAHL 120 
RAT             QTIQTEYFYLTPNLINDTIELREFQTTDDQCVYNFTHLGVQRENGTLSKCAGAVKIFAHL 120 
HUMAN           QEIQATFFYFTPNKTEDTIFLREYQTRQDQCIYNTTYLNVQRENGTISRYVGGQEHFAHL 119 
BOVINE          RAIQAAFFYLEPRHAEDKLITREYQTIEDKCVYNCSFIKIYRQNGTLSKVESDREHFVDL 120 
                : :*: :**: ..  :*.:  ** **  *:*:** :.: . *:***:*:  .  : *..* 
 
MOUSE           IVLRKHGAFMLAFDLKDEKKRGLSLYAKRPDITPELREVFQKAVTHVGMDESEIIFVDWK 180 
RAT             IVLKKHGTFMLAFNLTDEN-RGLSFYAKKPDLSPELRKIFQQAVKDVGMDESEIVFVDWT 179 
HUMAN           LILRDTKTYMLAFDVNDEKNWGLSVYADKPETTKEQLGEFYEALDCLRIPKSDVVYTDWK 179 
BOVINE          LLSKHFRTFMLAASWNGTKNVGVSFYADKPEVTQEQKKEFLDVIKCIGIQESEIIYTDEK 180 
                :: :.  ::*** . .. :  *:*.**.:*: : *    * ..:  : : :*::::.* . 
 
MOUSE           KDRCGQQEKKQLELGKETKKDPEEGQA 207 
RAT             KDKCSEQQKQQLELEKETKKETKKDP- 205 
HUMAN           KDKCEPLEKQH---EKERKQEEGES-- 201 
BOVINE          KDACGPLEKQH---EEERKKETEAS-- 202 
                ** *   :*::    :* *::   .   
 
Amino acid sequence alignment and homology comparison of AGP’s primary structures of α1-acid 
glycoprotein from different species. The accession numbers (Swiss-Prot) are the following: mouse Q60590, 
rat P02764, human P02763, bovine AJ844606. 
 
 
 
 
 
AGP is comprised of a single polypeptide chain of  201-207 residues, depending 
on the species, two disulphide bridges linking cysteine pairs 5-147 and 72-165 
(Schmid 1974) which play a crucial role for its correct folding and intramolecular 
and intermolecular interactions (Nishi 2006).   
The aa backbone of human AGP has been resolved to 1.8 Å and was found to fold 
in a typical lipocalin tertiary conformation (Schonfeld 2008). This structure is 
comprised of 1) an eight stranded beta-barrel as a central folding motif, 2) a 
flanking α-helix, and 3) four loops connecting the β-strands to form the entrance 
to a ligand-binding pocket at the open end of the β-barrel. 
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The refined crystal structure of human AGP at 1.8A resolution shown as a ribbon cartoon in stereo 
view. Secondary structure is colored yellow (β-strands), pink (α-helix), and gray (coils), while the 
two disulphide bridges are shown in orange. The open end of the β-barrel is highlighted in cyan. 
The 5 N-glycosylation sites and the residue Trp25 (conserved throughout the lipocalin family) are 
depicted as blue sticks.  
(Schonfels 2008). 
 
Earlier studies indicate that AGP has a wide and flexible drug-binding area to 
which both acidic and basic drugs can bind with considerable overlap (Maruyama 
1990). In fact, the nonglycosylated AGP presents a cleft-like cavity that measures 
9-12Å in diameter, is  ~18Å deep, and contains three distinct lobes, a main deep 
nonpolar lobe flanked by two smaller negatively-charged lobes (Schonfeld 2008). 
The intricate geometry of the cavity and the flexibility of its structure, explains the 
broad spectrum of basic and neutral compounds that can be engaged by this 
lipocalin ( Schonfeld 2008, Israili 2001). 
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Glycosylation 
 
AGP is heavily glycosylated. Approximately 45% of it’s 43kDa molecular mass 
can be attributed to attached sugar chains, presenting 5 N-glycosylation sites 
(Asn-15, -38, -54, -75, -85) that are not conserved across species lines. These 
glycans contain a wide range of sialo-oligosaccharides, being one of the few 
serum glycoproteins that can express di-, tri- and tetra-antennary N-linked glycans 
(Fournier 2000, Ceciliani 2007). 
 
 
 
List of sialo-oligosaccharide structures found in human, bovine, and rat AGP. (Ceciliani 
2007) N indicates N-acetylneuraminic acid (NeuAc). G indicates N-glycolylneuraminic acid 
(NeuGc). For detailed description of the structures refer to the paper of Dr.Nakano 2004. 
(Courtesy of Dr.Nakano) 
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Of these glycans, 10-12% are terminated by a sialic acid residue (NeuAc), each 
coupled through α(2-3) or α(2-6)  linkages to a subterminal galactose residue. This 
high sialylation state is responsible for the low pI (2.8-3.8) of AGP (Ceciliani 
2007). 
 
Structure of N-acetylneuraminic acid (Neu5Ac), the main representative of the sialic acid 
family, and some of its modifications (Lamari 2002) R4: acetyl, R7: acetyl, R8: acetyl, methyl, 
sulfate, R9: acetyl, phosphate, lactoyl. (Ceciliani 2007) 
 
Such a high diversity of glycan expression would predict more than 105 distinct 
glycoforms of AGP. However, some combinations have not been described in 
nature. In fact, only 12-20 different glycoforms can be detected in healthy human 
serum (Ceciliani 2007, Treuheit 1992). The glycosylation pattern is strongly 
influenced by the pathophysiological condition of the host, including acute 
inflammation, pregnancy, severe rheumatoid arthritis, and alcoholic liver cirrhosis 
or hepatitis ( Fournier 2000, Biou 1991, Jezequel 1988, Biou 1989, Serbource-
GoguelSeta 1986, Wieruszeski 1988). The glycosylation site Asn-38 is located in 
the α-helix. A change in its glycosylation, might influence the tertiary 
conformation of the molecule and thus, its ligand-binding activity (Ceciliani 
2007). 
 
In addition to its 5 N-glycosylation sites, AGP also contains 8 potential 
phosphorylation sites, that vary in number and position depending on the species 
(Ceciliani 2007). Surprisingly, very little is known about the phosphorylation state 
of AGP and whether it regulates its biological function. 
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Gene Structure 
 
Human AGP is encoded in chromosome 9, in a 70kb region, encoded by 3 
adjacent genes: AGP-A, AGP-B, AGP-B’. 
AGP-A is the major gene product  expressed in liver, about 100-fold more than 
the other two AGP isoforms. AGP-B and AGP-B’ are identical and each only 
differs from AGP-A by 22 base substitutions (Fourniner 2000). These two genes 
are probably a result of a recent duplication (Dente 1987). 
AGP-A gene is constructed of six exons and five introns. The whole coding 
region is included in a 4.6kb HindIII fragment (Dente 1987) that includes the 
coding region plus a 5’ and a 3’- flanking DNA region that are 1.2kb and 2kb 
long, respectively (Dente1988). 
The cDNA is 823bp long, with 78 untranslated bases at the 5’ end and 143 
untranslated bases at the 3’ end, adjacent to the polyA tail (Dente 1985). 
 
Rat AGP is encoded by a single gene (Liao 1985). 
Mus caroli has 8 genes encoding AGP (Prowse 1990). However only two of them 
are expressed at the protein level.  
BALB/c mice expresses two forms of AGP, AGP-1 and AGP-2, each encoded in 
chromosome 4 (Cooper 1986). Mice, as is true for rats, have the same gene 
structure for AGP as do humans, six exons and five introns (Fournier 2000). 
 
 
 
Regulatory elements and trans acting factors implicated in the expression of the AGP gene. 
The AGP gene promoter contains several positive cis-acting sequences within the SRU that are 
involved in its regulation by glucocorticoids: the GRE that binds the glucocorticoid receptor 
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interacting sith C/EBPβ; the upstream responsive elements (URE) and other regions that interact 
with C/EBPβ. All these elements are essential for maximal induction of the AGP promoter by 
glucocorticoids. The PBRE and the region probably involved in growth hormone response are 
located within the SRU, and interact with unknown factors (X factor), NF-kB and C/EBPα factors. 
The distal responsive element (DRE) implicated in the regulation of AGP by cytokines is located 
in the enhancer region and interacts with C/EBPβ. (Fournier 2000). 
 
AGP is a positive APP, and like serum amyloid A, haptoglobin and C-reactive 
protein, is regulated by  the pro-inflammatory cytokines, IL-1, IL-6, and IL-8 as 
well as by glucocorticoids (Fournier 2000). Retinoic acid can also indirectly 
modulate hepatic expression of AGP through increased IL-6 biosynthesis 
(Ceciliani 2007). 
 
During the acute phase response, the serum concentration of AGP not only 
increases but it’s glycosylation pattern changes. It’s sialylation and fucosylation 
states both change during an inflammatory process (Shiyan 1997) and these two 
modifications are independently regulated from its protein synthesis (DeGraaf 
1994,1995). 
Terminal sialic acids on AGP influence its half-life. Desialylation of AGP 
decreases its t1/2 from 5 days to 2 minutes (Weis 1989). 
 
 
AGP as a Binding and Transportation Protein 
 
AGP is one of the most abundant proteins in plasma (Schmid 1975). And together 
with albumin and the lipoproteins is one of the most important binding proteins in 
plasma. Its 3D structure, rich in β-sheets clearly resembles the conformation of a 
transport protein, the so called lipocalin signature (Schonfeld 2008). It has been 
demonstrated that in non pathological circumstances AGP can bind more than 300 
different molecules and drugs (Israili 2001). The binding and transport of some 
ligands, specially endogenous ones are probably involved in several important 
biological activities of the protein (Ceciliani 2007). 
Plasma AGP’s concentration is much lower than albumin  in physiological 
conditions, but during the acute phase response AGP becomes one of the most 
important binding/transporting protein for endogenous molecules since it’s 
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concentration is several fold increased while albumin’s, being a negative acute 
phase protein, decreases. In fact, during analbuminemia, AGP plays a major 
compensatory role by binding many amphipathic mediators becoming their 
principal carrier in the absence of albumin (Israili 2001).  
Due to it’s very special physical-chemical properties (pI 2.8-3.8) AGP can bind 
basic and neutral molecules. AGP can also bind endogenous ligands, such as 
heparin, IgG3, serotonin (Schmid 1972), platelet activating factor (PAF) 
(McNamara 1986), melatonin (Morin 1997), histamine (Chachaj 1980), and 
steroid hormones (McPherson 1980). Interaction of AGP with amphipatic 
mediators of inflammation such as PAF or PgE2 has also been reported (Ivanov 
2005). AGP is also the main vanilloids-binding protein in serum (Szallasi 1992) 
which can be inhibited by chlorpromazine and trisbutoxy-ethylphosphate 
indicating that AGP presents a specific binding domain for vanilloids. AGP can 
also bind acidic molecules like retinoic acid (Israili 2001), phenobarbital (Schley 
1983) and propanolol (Albani 1984) which is bound with different stereospecifical 
affinity, being (-)propanolol much easily bounded than (+)propanolol. Some other 
compounds have been found to have several binding sites, like estradiol, which 
can bind to 7 different sites (Kerkay 1968). 
Some of the molecules binded and carried by AGP also regulate its own 
expression (Ceciliani 2007). Retinoic acid is able to increase AGP gene 
expression in rat hepatocytes (Mouthiers 2004), whereas phenobarbital induces 
AGP gene overexpression (Mejdoubi 1999). AGP can also bind to toxic 
molecules produced by microorganisms such as toxic lectins (Frantz 2000) and 
bacterial lipopolysaccharide (LPS) (Libert 1994), thus serving as a general 
protective agent against septic shock.  
Endothelial cells constitutively produce AGP and export it to the glycocalyx 
where it plays an important role in maintaining capillar permeability (Haraldsson 
1987) where in rodent models has been shown to exhort a protective function by 
maintaining organ perfusions (Muchitsch 1998). 
AGP can also bind other serum proteins. In particular , AGP binds plasminogen 
activator inhibitor type 1 (PAI-1) (Boncela 2001). PAI-1 is a serpin (a serin 
protease inhibitor) and plays a very important role in the regulation of fibrinolysis. 
 18 
(Ceciliani 2007). It is usually complexed with vitronectin and circulates in this 
form (Declerck 1988). AGP has a much lower affinity for PAI-1 than vitronectin, 
but during the acute phase its concentration can be up to ten-fold higher (Berk 
1990) suggesting that AGP might act as a reservoir of the biologically active form 
of the protease inhibitor, specially during the acute phase. Moreover, during the 
acute phase, the complex AGP/PAI-1 may accumulate on the surface of the 
endothelium due to the high affinity of its glycan moiety to E-selectin on the 
endothelial cell surface, inducing a local generation of thrombin at the 
inflammation site (Ceciliani 2007). AGP as other lipocalins, is also involved in 
the transport of olfactory substances (Guiraudie 2003) in the nasal mucosa 
through the binding of lauric acid. 
 
 
 
NEUTROPHILS 
 
Neutrophils are the first line of defense against diverse forms of injury and 
invading bacteria. These cells arrive to the site of infection within minutes to 
neutralize the threat through multiple mechanisms. Neutrophils phagocytose 
bacteria,  produce reactive oxygen intermediates (ROI), and release antimicrobial 
contents of their granules (Borregaard 1997). Human neutrophils have secretory 
vesicles and primary (azurophilic) and secondary (specific) granules that contain 
antimicrobial proteins and proteases that, upon activation, are released at the site 
of tissue injury. Small ruminants and cows also have a unique, large type of 
granules that are not shared by humans (Gennaro 1983). Whereas the contents of 
both granules and secretory vesicles have been biochemically characterized, their 
mobilization and regulation are poorly understood. Contents of those granules are 
cytotoxic and essential to oppose infections but at the same time failure to control 
their release can provoke massive damage to the surrounding tissues (Smith 
1994). 
In both human and bovine species, two distinct isoforms of AGP can be found. 
One highly glycosylated AGP isoform has a high MW (50-60 kDa) and is 
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synthesized in myeloid cells in the bone marrow where they are and stored in 
secondary granules (Theilgaard-Monch 2005). Another far less abundant AGP 
isoform has a much lower MW (42-45 kDa) and after its release from the liver is 
endocytosed by neutrophils where it is stored in secretory vesicles (Rahman 
2008). 
 
Upon neutrophil activation, secretory vesicles are the very first ones to be 
released, readily followed by secondary granules. This pattern of release indicates 
that AGP exerts both local and systemic immunomodulatory activity (Fournier 
2000).  Even if the amount of AGP released by neutrophils at the inflammatory 
site might seem “not important” compared to the plasma AGP we can’t  exclude 
it’s relevance since it’s known that as little as 1µg/ml of AGP increases the 
cytosolic Ca2+ in humans (Gunnarsson 2007). 
The distinct molecular weights of the two isoforms found in neutrophils are due to 
different post-translational modifications which suggests that glycosylation does 
not only depend on the physiological state of the host but also on the tissue that 
expresses the protein (Rahman 2008). 
 
AGP is not only stored in neutrophils it also binds to its membranes regulating 
different activities. As little as 1µg/ml of AGP rises neutrophil cytosolic [Ca2+] in 
humans (Gunnarsson 2007) and acute phase concentrations (0.9mg/ml) diminish 
exocytosis of specific granules in bovine (Miranda-Ribera 2010). 
 
 
 
THE ENDOTHELIUM 
 
The microvascular endothelium presents a selective barrier that actively regulates 
movement of circulating fluid, macromolecules, and cells into extravascular 
tissues and compartments. Several distinct intercellular junctions regulate the 
paracellular movement of high molecular weight proteins, lipids and cellular 
mediators of the immune system. While some endothelia like the cerebral 
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microvasculature express predominantly tight junctions, other endothelia like the 
hepatic endothelium contain much larger gaps permitting the passage of larger 
molecules. Since this heterogeneity not only involves cell junctions, but also 
surface antigen expression and growth factor responsiveness, it is crucial to study 
each distinc type of endothelium (Prudence 1993). 
 
AGP plays a vital role maintaining normal endothelial barrier integrity in rat 
skeletal muscle (Haraldsson 1987). Similar results were shown in frog mesenteric 
capillaries (Curry 1989). In both cases, AGP was required to maintain the 
capillary charge barrier, due to it’s low pI of 2.7 rather than a change in the 
equivalent pore radius since the hydraulic conductivity never changed. These 
same findings were extended to the very specialized structure of the glomerulus 
(Haraldsson 1992) where AGP was needed to maintain normal barrier function. 
Moreover, dermal human endothelial cells synthesize their own AGP (Sorensson 
1999) to help maintain their own intrinsic charge selectivity. The interaction of 
AGP with the endothelial glycocalyx has not been fully studied. However, AGP is 
known to  affect the 3D arrangement of collagen and bovine serum AGP (boAGP) 
binds to the surface of bovine pulmonary microvascular endothelial cells 
(BLMVEC) (Schnitzer 1992)  in a ligand-receptor manner even if the receptor has 
not yet been defined. 
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AGP IN NEUTROPHIL GRANULES AND ITS EFFECT 
ON DEGRANULATION 
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Introduction 
 
Innate immunity strongly relies on the activity of polymorphonuclear (PMN) 
neutrophil leukocytes. They represent the first line of defence against invading 
pathogens by migrating to sites of infection within minutes from any injury, in 
order to search and destroy foreign intruders (Smith 1994). Neutrophils fulfil their 
role mainly by internalizing and exposing pathogens to the destructive action of 
reactive oxygen species (ROS) and hydrolyzing enzymes stored in their granules 
(Roos 2003). Bovine neutrophils, like other species, contain secretory vesicles, 
primary (azurophilic) and secondary (specific) granules. In addition, bovine and 
other small ruminants, such as goats and sheep, share unique, large, granules that 
are not present in human cells (Gennaro 1983, Paape 2003). While the 
organization of granules in bovine neutrophils is known, there is a relative lack of 
knowledge about the molecules which modulate their mobilization. Neutrophil 
exocytosis occurs due to the translocation of granules. This process is hierarchical, 
secondary granules being mobilized more readily than primary ones, in humans as 
well as in bovines (Watson 1995, Borregaard 1997, Paape 2003), and it is likely to 
be dependent on specific remodelling events. Due to their very high destructive 
potential, both PMN and organism as a whole have developed tight controlled 
mechanisms whose role is down regulating and limiting the destruction of 
surrounding cells and tissues (Serhan 2005). The resolution of the neutrophil 
phase of inflammation depends on the fine tuning of their lifespan, regulated by 
apoptosis, but also by the presence of molecules that may act as down regulators 
of the PMN action. The immunocalin  α1-acid glycoprotein (AGP) possesses an 
immunomodulatory activity and it is believed to play an important role in the 
regulation of local inflammatory reaction, for example by reducing the tissue 
damages caused by an excessive activation of complement (Tilg 1993). The 
concentration of AGP rises in plasma from three to five folds during systemic 
reaction of inflammation (Hochepied 2003, Petersen 2004), and therefore is 
considered, at least from a clinical perspective, a minor acute phase protein. AGP 
is mainly synthesized by liver, but it can be localized in several other human 
(Hochepied 2003) and bovine (Lecchi 2008) tissues. AGP exerts a sort of 
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protective activity by reducing the apoptosis rate in some inflamed tissues (Van 
Molle 1997) and by increasing the lifespan of monocytes, at least in the bovine 
species (Ceciliani 2007). Defensive functions of neutrophils can be affected as 
well: for example, AGP has been reported to influence neutrophil chemotaxis 
(Laine 1990, Vasson 1994), aggregation and generation of reactive oxygen 
species (Costello 1984). The activity of AGP on neutrophils exocytosis has not 
been investigated so far, neither in human nor in veterinary medicine. Our 
hypothesis is that, due to its well known immunomodulatory function, AGP acts 
as a local regulatory mechanism that modulates the exocytosis of granules from 
bovine neutrophils after their recruitment in the inflammatory focus. Therefore, 
the major aim of this study was to investigate the capability of purified bovine 
AGP to influence the degranulation of neutrophils by studying the possible 
relationship between AGP and the exocytosis of primary and secondary granules. 
The hypothesis that AGP may modulate neutrophil degranulation by competing 
with inflammatory mediator receptors, which in our experimental design included 
ZAS, was also explored. Finally, since AGP is one of the most glycosylated 
protein in the organism, and its glycan pattern strongly influences its biological 
activity [3], in the last part of this study the relationship between the terminal 
sialic acid residues of AGP and its exocytosis-modulating activity was 
investigated by using in parallel a desialylated glycoform. 
 
Materials and Methods 
 
Reagents 
All reagents used in these experiments were purchased from Sigma-Chemicals 
Co., unless otherwise specified. Hanks balanced saline solution with 0.5 mM 
CaCl2 and 1mM MgCl2 (HBSS+) was used throughout all the experiments. NaCl 
solutions were diluted starting from sterile cell tested 5M NaCl. Cell culture 
tested, endotoxin free, albumin was purchased from GIBCO (Invitrogen S.R.L. – 
Milano, Italy). Bovine serum was activated with 15 mg/ml of Zymosan A from S. 
cerevisiae at 37°C for 60 min. The mixture was then incubated at 56°C for 30 
minutes to destroy complement components with the exception of C5a. Zymosan 
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particles were removed by centrifuging the mixture for 15 minutes at 1000 x g at 
4°C. The obtained supernatant was filtered through a 0.22µm filter membrane 
(Millipore, Segrate, Italy), stored at -80°C and used within three months. 
Degranulation was induced using the ZAS stock solution diluted 1:5 vol/vol with 
HBSS+. All the experiments carried out in this study used bovine AGP aliquots 
purified from plasma as previously reported (ceciliani 2007). Two different 
concentrations of purified AGP were used: low concentration, similar to that 
physiologically found in bovine plasma of healthy subjects (0.3 mg/ml) and high 
concentration, similar to that found in bovine plasma during acute phase response 
to several inflammatory statuses (0.9 mg/ml) (Tamura 1989). 
 
Bovine neutrophils isolation 
Clinically healthy lactating Holstein cows between 2 and 7 years of age were used 
throughout these studies as blood donors for all experiments. Blood was obtained 
from the jugular vein and collected into blood bag containing acid-citrate-dextrose 
(Terumo, Belgium). Samples containing les than 5% eosynophils were used. 
Neutrophils were isolated using a Percoll®-gradient as previously described 
(Rinaldi 2007), with slight modification. Briefly, 40 ml of blood were transferred 
to 50 ml polypropylene conical tubes and centrifuged (1000 × g) for 20 minutes at 
4 °C. The plasma and buffy coat were aseptically aspirated and discarded. The 
remaining cells were suspended in 35 ml final volume of ice-cold PBS and the 
suspension slowly pipetted down the side of a clean 50 ml polypropylene conical 
tube containing 10 ml of 1.087 g/ml Percoll®. Samples were centrifuged (400 × g) 
for 40 minutes at 20°C. The supernatant, mononuclear cell layer, and Percoll® 
were aseptically aspirated and a pellet composed of PMN and erythrocytes was 
retained. Erythrocytes were lysed by mixing 1 volume of cells with 2 volumes of 
an ice cold 0.2% NaCl solution and inverting the tube for 1 minute. Tonicity was 
restored by the addition of one-half volume of a 3.7% NaCl solution. The samples 
were centrifuged at 500 × g for 2 minute at 4° C. Lysis were usually repeated, 
sometimes twice, using pre-warmed (37°C) Red Blood Cells Lysis Buffer. The 
cell pellet was washed twice by resuspension in PBS and recentrifugation for 2 
minute at 4°C. Cells were enumerated using an automated cell counter. Cell 
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viability and differential cell counts were determined by trypan blue exclusion and 
Wright staining, respectively. Neutropbhils purity was >95% and viability >90%. 
Cells concentration was adjusted with HBSS+ and maintained on ice until used in 
the various assays described below. 
 
Immunocytochemistry studies related to AGP binding to bovine neutrophils 
In order to verify if the activated bovine neutrophils were capable to bind AGP on 
the membrane surface, 1.5x105 neutrophils were stimulated for 30 minutes with 
AGP at 0.3 mg/ml and 0.9 mg/ml.  
The cells were centrifuged at 500 x g for 8 minute at 4°C, washed twice with cold 
PBS in order to remove unbound AGP molecules and stabilized with 1% 
formalin. Cells were allowed to settle on a glass slide and processed to assess 
AGP localization by immunofluorescence. After an incubation of 30 minutes at 
26°C in PBS containing 1% BSA and 1% NDS (Normal Donkey Serum), the 
slides were incubated overnight at 4°C with a polyclonal rabbit anti-bovine AGP 
(17 µg/ml in Dulbecco-modified PBS) (Ceciliani 2007). After the incubation, the 
samples were washed twice in PBS and stained with a fluorescein isothiocyanate 
(FITC) conjugated donkey anti-rabbit IgG antibody (1:200) for 30 minutes at 
26°C. Chromatin DNA was stained with DAPI (0,05 µg/ml in PBS). As negative 
control, the primary antibody against AGP was omitted in one slide for each 
experiment. All samples were mounted with an anti-fade medium and observed 
with a conventional epifluorescence microscope (Nikon, Eclipse E 600). 
 
Neutrophil degranulation studies 
Experimental design for the stimulation of the cells. 
Degranulation responses of neutrophils were investigated by studying the effect of 
AGP on the exocytosis of primary (azurophil) and secondary (specific) granules. 
All the experiments were carried out at 37°C in a sterile 96-well flat bottom 
ELISA plates (Becton Dickinson). Cells were incubated in different conditions as 
described below. The supernatant of each well was then transferred in an 
Eppendorf tube, centrifuged at 400 x g for 7 minute at room temperature (RT) and 
divided in two aliquots for the evaluation of granules exocytosis. 
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Primary and secondary granules release was determined by measuring the 
enzymatic activity of myeloperoxidase (MPO) (Quade 1997) and alkaline 
phosphatase (ALK-P) (Rausch 1975), respectively, which were assayed from the 
supernatants obtained from 2 x 106 cells in 200µl. The assay of alkaline 
phosphatase enzymatic activity exocytosed by specific granules was carried out 
following a slight modification of a previously established protocol (coomber 
1997). To 33µl of supernatant, 100µl of p-nitrophenyl phosphate (pNPP) ready 
made solution were added in 96 wells non sterile ELISA plates, and the mixture 
was incubated for 10 minute at RT. The reaction was finally blocked by the 
addition of 50µl NaOH 3M, and the plates were read at an absorbance of 410nm. 
MPO activity contained in primary granules was assayed on 50 µl of supernatant: 
200µl of tetramethylbenzidine (TMB) ready made solution were added. The 
reaction was carried out for 30 minutes at RT, and finally blocked by adding 50µl 
H2SO4 1M. The plates were read at an absorbance of 450 nm. 
Background values were calculated from wells containing pNPP and TMB, in 
their respective assay, added with 33µl and 50µl of HBSS+ respectively, and the 
results were automatically subtracted from all values.  
The data were expressed as the percentage of ALK-P, or MPO, activity compared 
to the total enzyme content of the cells, as determined after incubation of the same 
amount of cells with 0.5% hexadecyltrimethylammonium bromide (CTAB).  
Supernatants were then transferred into 96-well flat bottom non sterile ELISA 
plates and enzymatic activities were measured on automatic microtiter plate 
reader Multiscan MS (Labsystem, Helsinki, Finland). 
 
The experimental design was planned as follows: 
Experiment 1. In a first series of experiments, the cells were incubated with the 
two different concentrations of purified AGP in order to study the effect of two 
different concentrations of AGP on spontaneous degranulation of cells. Negative 
controls were neutrophils incubated with an equal volume of HBSS+ instead of 
AGP. MPO and ALK-P activities were measured after 120 minutes of incubation 
at 37°C and at 5% CO2 as previously described. 
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Experiment 2. In this second series of experiments, isolated neutrophils were 
incubated with two different concentrations of purified AGP and, in the 
meanwhile, challenged with ZAS. Positive controls were neutrophils incubated 
with ZAS and HBSS+ instead of AGP. Negative controls were non activated 
neutrophils in which equal volume of HBSS+ was added instead of ZAS and 
AGP. 
In order to rule out any unspecific protein activation, cells were further challenged 
with 0.9mg/ml albumin. Time course incubation was carried out for 0, 15, 30, 60, 
120 and 240 minutes.  
Experiment 3 was designed in order to verify if AGP’s activity was due to 
interaction of the protein with neutrophil membrane. Isolated neutrophils were 
therefore pre-incubated with two different concentrations of purified AGP for 10 
minutes. Unbound protein was washed away by centrifugation (200 x g for 7 
minutes) and cells were resuspended in HBSS+ and incubated with ZAS for 120 
minutes. MPO and ALK-P activities were measured as described. 
Experiment 4 was aimed to assess the importance of the glycan pattern of AGP 
for its degranulation-modulatory activity. In the last series of experiments de-
sialylated AGP ( as-AGP) was prepared by treating purified AGP with 200 mU/ml 
neuraminidase (streptococcus 6646K, EC 3.2.1.51) in 0.01 M sodium phosphate 
buffer, pH 6.0, for 2h at 37°C, exactly as previously reported (Ceciliani 2007). 
Isolated neutrophils were then incubated with two different concentrations of 
purified as-AGP. In the last group of experiments, neutrophils exocytosis was also 
challenged with ZAS. Aliquots of protein which were not submitted to 
neuraminidase treatment were used as controls. ALK-P and MPO activities were 
measured after 120 minutes, following the protocols previously described.  
Statistical analysis 
All statistical procedures were computed by using statistical software (SPSS 15.0, 
SPSS Inc., Chicago, USA). Results are expressed as mean values plus or minus 
standard error of the mean values. Different treatments were compared using a 
non parametric Wilcoxon test for paired samples. Statistical significance was 
accepted at P<0.05. 
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Results 
 
AGP binds to the surface of neutrophils 
With the aim to investigate if AGP may react with the surface of cells, resting 
granulocytes were labelled for AGP immunoreactivity by using the polyclonal 
anti-bovine AGP antibody. Results are presented in Fig. 1. The incubation of the 
cells with AGP resulted in a homogeneous fluorescent staining of PMN surface. 
This anti-AGP immunoreactivity apparently increases when neutrophils are 
treated with acute phase concentrations of AGP (0.9 mg/ml) (Fig.1: panel C). Fig. 
1 therefore shows that exogenous plasma AGP is capable to bind the surface of 
bovine neutrophils.  
 
Fig. 1: binding of AGP on the surface of neutrophil membrane 
Isolated neutrophils were treated with HBSS (Panel A), used as negative control, 0.3 mg/ml AGP 
(Panel B) and 0.9 mg/ml AGP (Panel C). Cells were immunostained with polyclonal rabbit anti-
bovine AGP (Ceciliani et al., 2007) as primary antibody, and donkey anti-rabbit FITC conjugated 
secondary antibody. Right Panels (Panels A1, B1 and C1) present the same cells after DAPI 
nucleus-specific staining (blue colour). 
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AGP modulates spontaneous degranulation (Experiment 1) 
 
The first series of experiments was designed to determine whether AGP may 
modulate spontaneous degranulation of secondary (specific) and primary 
(azurophilic) granules. Results are presented in Fig. 2. The treatment of cells for 
120 minutes with AGP fulfils a protective effect against spontaneous exocytosis 
of secondary granules (Fig. 2A), since ALK-P activity, which was used as a 
marker of secondary granules exocytosis, dropped from 7.04 ± 0.92 % (mean ± 
SEM) of the HBSS treated cells to 1.89 ± 1.03 % of AGP incubated cells (P < 
0.05). This effect is dose-dependent, the physiological concentration being non 
effective. The effect of AGP on primary granules spontaneous exocytosis is 
apparently opposite (Fig. 2B), since MPO activity, which was used as a marker of 
secondary granules exocytosis, increases from 2.85 ± 1.22 % of the HBSS treated 
cells to 7.97 ± 4.01 % of 0.9 mg/ml AGP-treated neutrophils. Due to the very high 
individual variability, this effect is not statistically significant. This effect of AGP 
on primary granules spontaneous degranulation can be appreciated only when 
cells are treated with acute phase concentration of AGP. Treating the cells with 
physiological concentration of AGP had apparently no effect. 
 
Fig. 2: the effects of AGP on neutrophil spontaneous degranulation Isolated neutrophils (6 
cows) were incubated with two different concentrations of AGP (0.3 mg/ml and 0.9 mg/ml) or 
HBSS (negative controls). After 120 minutes, alkaline phosphatase (ALK-P) (Panel A) and 
 30 
myeloperoxidase (MPO) (Panel B) enzymatic activities were measured in the supernatant of 
neutrophil culture as markers for secondary and primary granules exocytosis, respectively. Values 
are expressed as percentages of ALK-P and MPO enzymatic activity compared to total ALK-P and 
MPO activity in neutrophils lysed with CTAB (mean ± SEM). Statistically significant differences 
between AGP and negative controls (neutrophils treated with HBSS instead of AGP) were 
indicated as * (P < 0.05).  
 
 
AGP modulates the exocytosis of secondary granules induced by ZAS (Experiment 
2) 
The effects of AGP on secondary granules exocytosis are presented in Fig. 3A. 
The isolation procedure that was carried out to obtain the cells from clinically 
healthy animals was sufficient to induce a slight activation of neutrophils, as 
shown by the release of 5.05 ± 0.51 % of the total ALK-P content from non 
stimulated cells at T0’. When neutrophils are stimulated with ZAS, which 
cointains soluble C5a complement fraction derived from normal serum after 
activation with Zymosan, the enzymatic activity of ALK-P released from positive 
controls increases from 12.92 ± 2.95 % (T0’) to 45.17 ± 3.67 % (T240’). 
The incubation of the cells with 0.9 mg/ml albumin, carried out to rule out an 
unspecific protein activation of the cells, gave no significant difference when 
compared to positive control, since it ranges from 10.97 ± 1.32% (T0’) to 42.57 ± 
6.44% (T240’). When neutrophils are incubated with physiological concentration of 
AGP the response is bi-phasic and time-dependent: after the first 15 minutes lag it 
cannot be observed any statistically significant difference between AGP-treated 
cells, which ranges between 10.88 ± 2.59% (T0’) and 13.93 ± 1.34 % (T30’), and 
positive controls, which ranges between 12.92 ± 2.95% (T0’) and 21.28 ± 2.67 % 
(T15’). On the contrary, starting from T30’, it becomes evident that AGP, even 
when administered at physiological concentration, can reduce the activity of 
ALK-P. This inhibitory activity reaches it highest point at T240’ (26.98 ± 2.49% 
versus 45.17 ± 3.67 % of positive controls). 
The inhibitory activity of AGP toward secondary granules exocytosis is still more 
evident when neutrophils are treated with acute phase concentration of protein, 
similar to those found in plasma during the systemic response to inflammation. 
The degranulation of secondary granules is almost immediately inhibited when 
compared with positive controls (at T0’ ZAS/AGP = 6.71 ± 1.87% versus positive 
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controls = 12.93 ± 2.95%). This inhibitory activity is steadily increasing over 
time, and reaches its highest point at T240’ (ZAS/AGP = 9.15 ± 1.26% versus 
45.17 ± 3.67% of positive controls). The down-regulating effect of acute phase 
concentration of AGP on secondary granules exocytosis is statistically significant 
starting from T15’ incubation. 
The effects of AGP on primary granules exocytosis are presented in Fig. 3B. 
Again, the isolation procedure carried out to obtain the cells from clinically 
healthy animals was sufficient to induce a slight activation of neutrophils, as 
shown by the release of 3.19 ± 0.60 % (mean ± SEM) of the total MPO content 
from non stimulated cells at T0’. The challenging of bovine neutrophils with ZAS 
induces an immediate exocytosis of primary granules, as indicated by the high 
MPO enzymatic activity at T0’ ( 37.91 ± 8.13 % of the total MPO activity). 
Incubation of ZAS-activated neutrophils with albumin (0.9 mg/ml) and AGP at 
both concentrations apparently has no effect on the primary granules exocytosis. 
Moreover, the release of MPO is not time-dependent, since it does not change 
from T0’ to T240’. 
In conclusion, the results presented in Fig. 3 demonstrated that the treatment of 
ZAS-activated neutrophils with AGP purified from bovine serum selectively 
reduces the release of secondary granule content in a dose-dependent way, and 
apparently has no effect on that of primary granules.  
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Fig. 3: the effect of AGP treatment on secondary and primary granules exocytosis Neutrophils 
were isolated from 7 cows and incubated with AGP at two different concentrations: physiological 
concentration (0.3 mg/ml) and acute phase concentration (0.9 mg/ml). Albumin (0.9 mg/ml) was 
used in order to rule out any unspecific protein activity.  Degranulation of secondary granules was 
induced with ZAS as described in Materials and Methods. Positive controls were neutrophils 
treated with ZAS and HBSS instead of AGP. Negative controls were HBSS treated cells without 
ZAS. Panel A presents alkaline phosphatase (ALK-P) activity in the neutrophil culture 
supernatant, used as marker of secondary granules exocytosis. Panel B presents myeloperoxidase 
(MPO) activity in the neutrophil culture supernatant, used as marker of primary granules 
exocytosis. Values are expressed as percentages of ALK-P and MPO activity compared to total 
ALK-P and MPO activity in neutrophils lysed with CTAB (mean ± SEM). Statistically significant 
differences between the two concentrations of AGP and positive control (neutrophils activated 
with ZAS and treated with HBSS instead of AGP) were indicated as * (P < 0.05). The differences 
between positive and negative controls were all statistically signifcant, and were not indicated in 
the figure. 
 
 
 
The pre-incubation of cells with AGP reduces the exocytosis of neutrophil 
granules induced by ZAS (Experiment 3) 
In order to verify if one of the possible mechanisms of action of AGP was the 
interaction with the molecules that are believed to be involved in the binding of 
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ZAS-generated by-products, e.g. C5a receptor (i.e. CD88), isolated neutrophils 
were pre-incubated with AGP for 10 minutes, after which exocytosis was induced 
by ZAS. Results are presented in Fig. 4. The pre-incubation of cells with AGP 
does not modify the exocytosis of primary granules (Fig. 4B). On the contrary, 
Fig. 4A shows that the enzymatic activity of ALK-P used as marker for secondary 
granules exocytosis is decreased, from 20.30 ± 4.55% of the positive controls to 
9.46 ± 1.64% of the AGP’s (0.9 mg/ml) pre-incubated cells after 120 minutes of 
incubation with ZAS (P < 0.05) While there is a decrease of secondary granules 
exocytosis also when cells are pre-treated with physiological concentration of 
AGP (14.64. ± 2.18%), this result is not statistically significant when compared to 
positive control. 
 
 
Fig. 4: the effect of neutrophil pre-incubation with AGP on primary and secondary granules 
exocytosis Neutrophils were isolated from 4 cows and pre-incubated for 10 minutes with 
physiological (0.3 mg/ml) and acute phase (0.9 mg/ml) concentrations of AGP, and HBSS. 
Unbound protein was removed by centrifugation, and degranulation was induced by treating the 
 34 
cells with ZAS for 120 minutes. Negative controls were HBSS treated cells without ZAS. Positive 
controls were neutrophils treated with ZAS and pre-incubated with HBSS instead of AGP. 
Alkaline phosphatase (ALK-P) (Panel A) and myeloperoxidase (MPO) (Panel B) enzymatic 
activities in the neutrophil culture supernatant were used as marker of secondary and primary 
granules exocytosis, respectively. Values are expressed as percentages of ALK-P and MPO 
enzymatic activity compared to total ALK-P and MPO activity in neutrophils lysed with CTAB 
(mean ± SEM). Statistically significant differences between the two concentrations of AGP and 
positive control were indicated * ( P < 0.05). The differences between positive and negative 
controls were all statistically signifcant, and were not indicated in the figure. 
 
 
 
 
AGP effects on degranulation are related to its sialic acid content (Experiment 4). 
The last set of experiments was set out to determine the importance of the sialic 
acid residues exposed on the surface of AGP. Exocytosis studies were then 
performed using in parallel AGP aliquots purified from bovine serum and 
neuraminidase-treated AGP (as-AGP), in which terminal sialic acid residues were 
enzymatically removed. The reaction was carried out for 120 minutes. When 
neutrophils were activated with ZAS, as-AGP lost every inhibitory activity, which 
is retained by the olo-protein (Fig. 5A). The desialylation of AGP has no effect on 
primary granules (Fig. 5B). The spontaneous exocytosis down-regulatory effects 
of AGP on secondary granules is equally lost when sialic acid terminal residues 
are removed, as shown in Fig. 6A as well as the apparently up-regulatory activity 
on primary granules exocytosis, as shown in Fig. 6B. 
In conclusion, both inhibitory and up-regulatory effects on secondary and primary 
granules exocytosis, respectively, cannot be detected by using the desialylated 
protein. 
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Fig. 5: the effects of desialylation of AGP on its modulatory activity of neutrophil exocytosis. 
Isolated neutrophils (7 cows) were incubated with physiological (0.3 mg/ml) and acute phase (0.9 
mg/ml) concentrations of AGP before and after treatment with neuraminidase, which specifically 
removes terminal sialic acid residues. Degranulation of secondary (Panel A) and primary (Panel B) 
granules was induced with ZAS as described in Materials and Methods. HBSS and ZAS alone, 
without adding AGP, were used as positive control. Negative controls were HBSS treated cells 
without ZAS. After 120 minutes, alkaline phosphatase (ALK-P) (Panel A) and myeloperoxidase 
(MPO) (Panel B) enzymatic activities were measured in the supernatant of neutrophil culture as 
markers for secondary and primary granules exocytosis, respectively. Values are expressed as 
percentages of ALK-P and MPO enzymatic activity compared to total ALK-P and MPO activity in 
neutrophils lysed with CTAB (mean ± SEM). Statistically significant differences between the two 
indications of AGP and HBSS treated activated neutrophils (positive control) indicated as * (P < 
0.05). The differences between positive and negative controls were all statistically signifcant, and 
were not indicated in the figure. 
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Fig. 6: the effects of desialylated AGP on neutrophil spontaneous degranulation. Isolated 
neutrophils (5 cows) were incubated with two different concentration of AGP (0.3 mg/ml and 0.9 
mg/ml) before and after treatment with neuraminidase, which specifically removes terminal sialic 
acid residues. HBSS instead of AGP was used as negative controls. After 120 minutes, alkaline 
phosphatase (ALK-P) (Panel A) and myeloperoxidase (MPO) (Panel B) enzymatic activities were 
measured in the supernatant of neutrophil culture as markers for secondary and primary granules 
exocytosis, respectively. Values are expressed as percentages of ALK-P and MPO enzymatic 
activity compared to total ALK-P and MPO activity in neutrophils lysed with CTAB (mean ± 
SEM). Statistically significant differences between AGP and HBSS treated neutrophils (negative 
control) were indicated as * (P < 0.05). 
 
 
Discussion and Conclusions 
 
The activity of neutrophils is essential for the development of the first phase of 
innate immunity. Yet, they are very aggressive cells, and the extracellular release 
of ROS products, as well as the proteolytic enzymes contained in their granules, 
may cause massive tissue injuries during acute and chronic inflammation. Many 
acute phase proteins fulfil anti-inflammatory functions (Gabay 1999) directed 
toward the inhibition of these collateral damages of inflammation. In the first part 
of this study we provide evidence that one of them, the minor acute phase protein 
α1-acid glycoprotein, can modulate one of the most important functions of bovine 
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neutrophils, the mobilization of their granules. Spontaneous degranulation is 
affected in a dose-dependent way by AGP. The biological significance of this 
result is unknown, but we may speculate that at least one of the functions of the 
rise in serum concentration of AGP during acute phase reaction might be that of 
counteract a praecox degranulation of neutrophils while they are still in the blood 
stream. The apparently opposite effect on primary granules has still to be 
elucidated. The capability of AGP to down-regulate the mobilization of secondary 
granules was more evident when the cells were challenged with ZAS.  
The pathways regulating the specific mobilization of neutrophil granules are far to 
be clarified; nonetheless, granules translocation is known to depend on highly 
specific signals, i.e. their mobilization shows to be hierarchical, since primary 
granules are translocated after the secondary ones (Tapper 1996). Still it is to be 
queried how AGP might interfere with the molecular pathways driving to the 
exocytosis of neutrophil granules. AGP binds on the surface of neutrophil 
membrane, as shown by immunocytometry studies. It is therefore at least 
conceivable that the activity of AGP is due to the interaction with the protein on 
the surface of the cells. In order to verify the functional significance of this 
interaction, neutrophils were pre-treated with AGP, and then activated with ZAS. 
Since priming of neutrophils with AGP reduces the secondary granules 
exocytosis, it can be hypothesized that AGP might, at least partially, act by 
competing with the specific pathways which are activated by the pro-
inflammatory challengers used to stimulate the cells. Essentially the treatment of 
serum with Zymosan generated C5a that activated the cells by interacting with 
CD88, its specific receptor. It would be very interesting to determine whether the 
reduced exocytosis induced by AGP is due to the interaction of the protein with 
CD88, which may contribute to down-regulate the secondary signals necessary to 
integrate the inflammatory response triggered by C5a.  
And through still undisclosed mechanisms, AGP might modulate neutrophil 
granule exocytosis by binding to its specific receptors exposed on the surface of 
the cells. AGP’s binding sites on neutrophils are still poorly understood: at least 
two different binding sites have been identified on human granulocytes surface, 
with different binding affinities (Shiyan 1997). The molecular pathways activated 
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when these receptors interact with AGP are still unknown. AGP’s receptors on the 
surface of neutrophils are likely involved in cytoskeletal remodelling events that 
drive to the selective mobilization of granules. This hypothesis is supported by a 
recent finding (Gunnarsson 2007) which reported that AGP triggers Ca2+ 
mobilization in human neutrophils. Since the hierarchical mobilization of granules 
is due to different cytoskeletal activation, which is calcium dependent, we may 
speculate that the effects of AGP on the modulation of secondary granules 
traslocation are related to its capability of inducing the intracellular Ca2+ 
mobilization. 
Another possible mechanism of action of AGP can be assumed. As a binding 
protein, AGP might also act by sequestering some of the mediators, thus reducing 
their biological availability in the inflammatory environment. Further experiments 
should support such hypothesis; anyway, AGP can bind some inflammatory 
mediators such as PAF (Ojala 2006), as already shown in humans. 
All the exocytosis modulating activities of AGP shown in this paper are strongly 
related with its glycan moiety, since all of them were suppresed by the removal of 
sialic acid terminal residues exposed on the protein surface. These results are 
consistent with other reports (Costello 1979, Ceciliani 2007) demonstrating that 
the sialic acid residues are essential to some functions of the protein. A 
remarkable knowledge, since the glycosylation of AGP is strongly dependent on 
its physiological and pathological status. Furthermore, in accordance with above 
findings, other authors (Gunnarsson 2007) had previously demonstrated that sialic 
acid molecules exposed on the surface of the AGP are essential to increase Ca2+ 
concentration. Comparing the effect on granule exocytosis of plasma AGP and the 
hypersialylated and hyperfucosylated glycoforms present in secondary granules of 
neutrophils (Theilgaard-Monch 2005, Rahman 2008), or in serum during several 
inflammatory diseases (Ceciliani 2007) would be an interesting matter of 
investigation. In conclusion, our findings reported for the first time that AGP is 
able to specifically down-regulate the secondary granule exocytosis. Signalling 
mechanisms underlying the involvement of AGP in modulating neutrophil 
functions are still not known, and further studies are necessary to go insight the 
signalling capability of this immunomodulatory protein. 
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Introduction 
 
Angiogenesis is an important host response to injury, ischemia, and is crucial to 
the wound healing process. Angiogenesis is also central to tumor cell survival. As 
a tumor mass grows, it must promote new vessel formation to maintain a 
continuous supply of nutrients of oxygen, some tumors generate multiple 
proangiogeneic factors and signaling to encourage tumor angiogenesis.  
 
Angiogenesis or neovascularization is the process of generating new blood vessels 
derived from existing vascular structures. It is a multistep process that involves 
endothelial cells (Auerbach 2003). First, the basement membrane within the wall 
of a preexisting vessel is proteolytically degraded allowing ECs to disengage from 
neighboring cells and to migrate through the vessel wall to migrate towards the 
angiogenic stimulus (Auerbach 2003, Karamysheva 2007). Proliferation occurs 
behind the migrating front, to deliver an adequate number of cells to form the new 
vessel. The last step is the reorganization of the new migrated cells into a three 
dimensional tubular structure. In adults, the 4 steps of new vessel formation, 1) 
basement membrane disruption, 2)cell migration, 3)cell proliferation, and 4)tube 
formation (Auerbach 2003), are tightly regulated, and only activated under very 
defined conditions like wound healing (Karmaysheva 2007). 
The processes of cell adhesion, migration, invasion and proliferation are mediated, 
in part, by cell adhesion molecules (Brooks 1996) expressed by the endothelium. 
Some of these adhesion molecules include integrins like αvβ3 which is 
upregulated during angiogenesis (Brooks1994), immunoglobulins like VCAM-1 
(Koch 1995), and selectins like E-selectin, which is surface expressed on 
cytokine-activated vascular endothelium. Moreover, specific antibodies targeting 
E-selectin have been shown to block capillary tube formation, in vitro (Nguyen 
1993). 
 
Bovine serum AGP binds to bovine pulmonary microvascular endothelial cells 
(Schnitzer 1992) in a calcium independent manner that does not utilize lectin-like 
receptors, such as the asialoglycoprotein or mannose receptors.   Endothelium 
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binding sites specific for AGP, have been demonstrated but not fully characterized 
(Predescu 1998). AGP binding studies in a bovine system revealed comparable 
results as that seen in a human system. By binding to the endothelium, AGP plays 
a vital role in maintaining capillary permselectivity. It has been shown to be of 
crucial importance in maintaining the capillary charge barrier in rat skeletal 
muscle (Haraldsson 1987), guinea-pig skin (Muchitsch 1996), frog mesenteric 
capillaries (Curry 1989) and rat glomerular capillaries (Haraldsson 1992). 
Sorensson et al. also found that human dermal microvascular endothelial cells 
produced AGP that was immunolocalized to the glycocalyx where it helped to 
maintain the capillary barrier for macromolecules (Sorensson 1999). Transcytosis 
of AGP across the microvascular endothelium occurs rapidly, exclusively via 
caveolae (Predescu 1998). After its perfusion AGP can be detected in the 
perivascular space within one. As anticipated, AGP was not detected within 
intercellular space. 
 
 
Under physiologic conditions, the endothelium is not adherent for peripheral 
blood cells. Upon stimulation, the endothelium surface expresses multiple 
adhesion molecules, including P-selectin, E-selectin, intracellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Hack 
2001). During injury and inflammation, the endothelial surface becomes adherent 
for circulating leukocytes that adhere to, migrate across and traverse between the 
endothelial cells to enter the site of inflammation (Dauphinee 2005). Neutrophil 
adherence to vascular endothelial cells is the initial event in the emigration of 
neutrophils through blood vessels walls to tissue site of inflammation (Tonnesen 
1984). The first contact between neutrophils and endothelium of postcapillary 
venules is known as capture or tethering and is mediated by P and E-selectins 
expressed on the endothelium  that bind to both P-selectin glycoprotein ligand 1 
(PSGL1) and sialylated carbohydrates present on the surface of the neutrophils 
(Ley 2007, Zarbock 2008). This first PMN to- endothelium contact will cause the 
neutrophils to slow down and to start rolling along the activated endothelium 
surface, integrating  different chemokines that will cause the activation of the 
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neutrophil and will slow the rolling. The last step of the neutrophil recruitment is 
mediated by the integrins inter-cellular adhesion molecule 1 (ICAM1), vascular 
cell adhesion molecule 1 (VCAM1) and mucosal vascular addressin cell adhesion 
molecule 1 (MADCAM1), that will cause the neutrophil to stop and finally to 
crawl and transmigrate across the endothelium through the paracellular junctions 
to get to the inflammation site. 
Neutrophils constitute the first line of defense against invading bacteria (Zarbock 
2008). Neutrophil activation and recruitment to the inflammation site is not fully 
understood, but seems to be gradual  and mediated by several signaling pathways 
(Ley 2002). While essential to oppose infections, the activation of neutrophils can 
also release cytotoxic mediators, which may result in tissue damage. Therefore, 
neutrophil recruitment during inflammation is paradoxical; they are crucial for 
host defense, but if their recruitment and activation becomes dysregulated, they 
may also be involved in the development of tissue injury and organ failure 
(Rahman 2008).  
 
 
Taken together, the data clearly shows that endothelial cells produce, bind, and 
transport via a caveolae-dependent pathway, AGP. Further, AGP inhibits the 
action of histamine on endothelial cells in a cAMP-dependent manner (Sorensson 
2000). In the current studies, we studied the effect of AGP on in vitro 
angiogenesis, and PMN adhesion to endothelia. 
 
Plus since AGP, due to its glycan moiety, has a high affinity to E-selectin on the 
surface of endothelial cells (Ceciliani 2007) and E-selectin is known to be 
overexpressed in cytokine stimulated endothelium we wondered if AGP, as an 
anti-inflammatory molecule would have any effects on the PMN adhesion to a 
monolayer of HVEC-Ls. 
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Materials and Methods 
 
Preparation of Human α1-acid Glycoprotein: AGP was isolated by 
conventional HPLC ion exchange chromatography as described (Ceciliani 2007) 
with slight modifications. Briefly, human serum  was dialyzed against the buffer 
used for the initial chromatography (10 mM citrate–phosphate buffer, pH 4.0). 
The serum was centrifuged to remove proteins not soluble at pH 4.0, and the 
supernatant was applied to an HiTrap Q Sepharose strong anionic exchange 
column 1 ml (GE Healthcare) equilibrated with the starting buffer. The protein 
was eluted in 100 mM citrate–phosphate buffer, pH 4.0. The fraction containing 
AGP was concentrated with Centricon 10 (Millipore) to 1/10 of initial volume and 
directly loaded onto an HiTrap SP Sepharose (GE Healthcare) strong cationic 
exchange column, equilibrated in 100 mM citrate–phosphate buffer, pH 4.0. A 
final purification step was performed to remove endotoxins potentially introduced 
during the purification procedure. The fraction containing AGP was directly 
loaded on a Sephasil Protein C4 (5 µm ST 4.6/100 mm) chromatographic column 
(GE Healthcare) equilibrated with 0.065% TFA in 2% acetonitrile. Protein 
separation was accomplished using a 0–65% gradient of acetonitrile + 0.05% TFA 
over 33 min, at a flow rate of 1 mL/min. The fraction containing AGP was 
collected, concentrated to 1 mg/mL in a Savant microconcentrator, aliquoted and 
stored at -80ºC. 
 
Endothelial Cell Culture: Human lung microvascular endothelial cell (HMVEC-
L)s (Lonza) were cultured in EC growth medium (EBM-2, Clonetics) containing 
5% fetal bovine serum (Hyclone Laboratories, Logan, UT), human recombinant 
epidermal growth factor (EGF), human recombinant insulin-like growth-factor-1, 
human basic fibroblast growth factor, vascular endothelial growth factor, 
hydrocortisone, ascorbic acid, gentamicin, and amphotericin as described (Gong 
2008). Only HMVEC-Ls in passages 6 to 8 were studied. 
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EC Tube Formation Assay: Each well of a 96-well plate was coated with 30 µl 
of Matrigel (10 mg/ml; BD Biosciences, Bedford, MA) using a modification of 
previously described protocol (Yang 1996). Briefly, 30 µl of Matrigel on ice were 
allowed to polymerize for 1h at room temperature in each of the wells, followed 
by 1h at 37ºC in a humidified atmosphere of 5% CO2. HMVEC-Ls were seeded at 
2 x 104 cells/well onto the Matrigel-coated wells and cultured for 6h in medium, in 
the presence or absence of increasing concentrations of  AGP, BSA or media 
alone and observed for tube formation. At 6h, tubular structures were 
photographed and quantified with a Nikon inverted microscope through a 20X 
objective. 
 
EC viability assay: HMVEC-L’s at 104 cells per well were seeded into the wells 
of a 96-well plate for 24h at 37°C. The monolayers were treated for 0.5h or 6h 
with AGP 0.75mg/ml or medium alone. Cells were then washed with serum-free 
medium, incubated for 4h at 37°C with 0.5mg/ml of MTT (Sigma) followed by 
incubation with 10%SDS+0.01N HCl to solubilize the formazan product. Plates 
were read at A540nm (Versamax microplate reader, Molecular devices,Sunnyvale 
CA).  
 
EC Adhesion Assay: HMVEC-Ls were seeded in matrigel-coated wells of a 96 
well plate at 3x104 cells/well and incubated for 30 min at 37°C  in 
0.1%BSA/DMEM, in the presence or absence of increasing concentrations of 
AGP. After washing x2, adherent cells were stained with 0.2% crystal violet in 
20% methanol, washed with PBS, and the residual stain extracted with 1% SDS, 
and the A560nm of extracts measured. 
 
Migration in a Wounding Assay: HMVEC-Ls were seeded at 2x105 cells/well in 
the wells of a 24 well plate (Corning Glass, Corning, NY) and cultured to 
confluence. Using a sterile 200µl pipette tip, a single wound was made across the 
diameter of each monolayer, after which cell debris was removed by washing with 
HEPES as described (Liu 2009). The wounded monolayers were then incubated 
for 24h with AGP 0.75mg/ml or media alone. Photomicrographies of each well 
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were taken at times 0h, 5h, and 24h with a Nikon inverted microscope through a 
4X objective. In selected wash-out experiments, after 24h, monolayers were 
incubated with media alone and two more photomicrographies were taken at time 
36h and 48h. 
 
Endothelial Cell Chemotaxis Assay: Gelatin-impregnated polycarbonate filters 
(13 mm diameter, 8.0 µM pore size; Nucleopore Inc., Pleasanton, CA) were 
mounted in chemotactic chambers (Neuroprobe Inc., Gaithersburg, MD) as 
described (Sun 2001). HMVEC-Ls (5 x 104 cells in 100 µl) were added to the 
upper compartment of each assay chamber. Each lower compartment contained 
0.5% FBS as the chemoattractant. In selected experiments, AGP was introduced 
into either the upper or lower compartment in the presence or absence of FBS. 
After a 5h incubation (37oC, 5% CO2), filters were removed, fixed (3.7% 
formaldehyde in H2O, 30 min), washed, stained with 0.5% crystal violet in 25% 
ethanol, washed, and the top surface of each filter scraped free of cells. The 
crystal violet was then extracted from each filter with 0.1M citric acid in 50% 
ethanol for 30 min and the A560nm of extracts measured. 
 
Preparation and Fluorescent Labeling of PMNs: Whole peripheral blood from 
healthy human volunteers was collected under a protocol approved by the 
University of Maryland, Baltimore, Institutional Review Board, into acid citrate 
dextran (Sigma) solution, and PMNs were isolated by dextran erythrocyte 
sedimentation and density gradient centrifugation through ficoll-hypaque (Sigma) 
as previously described (Sakarya 2004). PMNs were resuspended in HBSS 
without divalent cations (HBSS–) at 5 x 106  PMNs/ml and were incubated with 5 
µM CalceinAM AM (Molecular Probes, Eugene, OR) for 30 min at 37oC (Welten 
2004). PMNs were washed three times with HBSS– after which their purity was 
>95% and viability >98% by trypan blue dye exclusion. 
 
PMN Adhesion Assay: HMVEC-Ls were seeded (1 x 104 cells/well) into the 
wells of 96-well culture plates (Costar, Cambridge, MA), and cultured to 
confluence (48 h, 37oC, 5% CO2). The HMVEC-L monolayers were preincubated 
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for 5h with LPS 100 ng/ml or media alone. CalceinAM-labeled PMNs were 
pretreated for 15 min with fMLP (10–6 M)/cytochalasin B (5 µg/ml) or media 
alone, washed, and incubated for 30 min at 37oC  with HMVEC-L monolayers (5 
x 104 PMNs/well) in the presence or absence of increasing concentrations of AGP 
or media alone. After gentle washing to remove nonadherent PMNs, the attached 
PMNs were flourometrically assayed (excitation 485 nm, emission 538nm) in a 
Cytofluor II Multi-well Fluorescence plate reader (PerSeptive Biosystems, 
Framingham, MA).  For each experiment, 5 x  104  labeled PMNs were used as a 
standard to which fluorescence units of adherent PMNs adhesion were compared 
and expressed as % adhesion ( adherent PMNs / total PMNs x 100%).  
 
Statistical Methods: Student t-test, with a two tailed distribution and an 
homoscedastic variance was used for all statistical analyses (Microsoft Office 
Excel 2003). Significance accepted for p values <0.05. 
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Results 
 
Preparation of Human α1-acid Glycoprotein: AGP was isolated from human 
serum by conventional HPLC ion exchange chromatogphy, using three different 
columns and finally getting a purified, endotoxin free, single protein.  
 
 
 
1 2
42 kDa
59 kDa
20 kDa
15 kDa
28 kDa
ii)
i)
 
 
Figure1.Preparation of Human α1-acid Glycoprotein: On the left (i) chromatogram of HiTrap 
SP Sepharose column, where AGP is eluted in the void volum. * indicate de absorbance pics, 
containing AGP that were collected and later analized. On the right (ii) Coommassie staining of 
the electrophoretic gel containing the purified protein. Lane 1 was loaded with 5µg of protein 
whereas lane 2 was loaded with 1µg of total protein. We can see a single band, showing that the 
final solution contains a single protein, and it is about 42kDa which is the expected molecular 
weight. 
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AGP Inhibits Endothelial Cell Capillary-Like Tube Formation: We asked 
whether the heavily sialylated, acute phase protein, AGP, might influence EC tube 
formation, ie in vitro angiogenesis, in a two-dimensional Matrigel system. After 
6h in the absence of AGP, a mean (±SE) of 32.5±3.4 tubes/HPF were detected 
(Figure2A and B). After 6h in the presence of increasing concentrations of AGP, 
it was possible to see an inhibition of the tube formation at concentrations as low 
as 0.25mg/ml even if they were not enough to be statistically significant. AGP at 
≥0.50mg/ml inhibited tube formation >70% with a maximum effect of 97% 
inhibition at 0.75mg/ml (Figure 2B). The statistical significance started at 
0.50mg/ml with a 73.8% decrease on the tube formatting and it reached it’s 
highest level at 0.75mg/ml with a 97.4% of inhibition. Showing that AGP inhibits 
EC tube formation on matrigel in a dose dependent manner. Bovine Serum 
Albumin (BSA) (Sigma) was chosen as a simultaneous protein control, and 
identical experiments were performed with the identical increasing concentrations 
of BSA but no significant activity could be seen (data not shown). 
 
 
 
Figure2A.(i) On the left, HMVEC-Ls were incubated for 6h on Matrigel. Arrows indicate 
capillary-like tubes. (ii) Identical conditions as described in (i) except the HMVEC-Ls were 
incubated in the presence of 0.75mg/ml AGP. Magnification 4X.  
 
 
 
i ii 
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Figure2B. AGP Inhibits Endothelial Cell Capillary-Like Tube Formation: HMVEC-Ls were 
treated with increasing  AGP concentrations, from 0mg/ml to 0.75mg/ml, and incubated for 6h on 
Matrigel in the wells of 96 wells plates. Photomicrographies were taken and tube length measured. 
Each bar represents mean (+/- SE) tube length, * indicates significantly decreased compared to the 
simultaneous medium control at p<0.05. 
 
 
EC viability assay: A MTT conversion assay was introduced to exclude AGP-
induced EC cytotoxicity; after incubation of EC for 6h with 0.75mg/ml AGP, no 
loss of cell viablility could be detected (data not shown). Therefore, AGP at 
0.75mg/ml does not provoke HMVEC-L cytotoxicity within 6h. 
 
  
AGP Inhibits EC Adhesion to Matrigel: We now have established that AGP 
inhibits the multistep process of in vitro angiogenesis (Figure 2). We asked 
whether this negatively-charged molecule might exert its anti-angiogenic effect 
through altered EC adhesion to the Matrigel substrate. Incubation of ECs with 
increasing concentrations of AGP promoted a biphasic effect of EC adhesion to 
Matrigel (Figure 3). At lower concentrations of 0.05-0.25mg/ml, AGP increased 
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EC adhesion with a maximal effect of +24.5% at 0.10mg/ml (Figure 3). In 
contrast, AGP at concentrations of  ≥0.50mg/ml decreased EC adhesion with 
mean maximal inhibition of -29.7% at 0.75mg/ml (Figure 3). These combined 
data indicate a biphasic AGP activity, at lower concentrations, AGP increased EC 
adhesion to Matrigel, whereas at higher concentrations, it diminished it.  
 
 
 
Figure3. AGP Inhibits EC Adhesion to Matrigel: HMVEC-Ls at 3x104cells per well were 
incubated for 30min in matrigel coated wells in the presence of increasing concentrations of AGP. 
After non adherent cells were washed away, remaining adherent cells were counted with a 
colorimetric assay (crystal violet dye) and then expressed as mean (+/- SE)  normalized to 
adhesion of the simultaneous medium control (closed bar). * indicates significantly increased 
compared to the medium control at p<0.05. ** indicates significantly decreased compared to the 
medium control at p<0.05. 
  
AGP Inhibits EC Migration in a Wounding Assay: We already know that AGP 
influences EC tube formation on (Figure 2) and EC adhesion to the glycocalyx 
(Matrigel) (Figure 3). We wondered if AGP could also inhibit EC migration into a 
wound. In a wounded HMVEC-L monolayer, we observed wound healing over 
time (cells migrated into the wound) in presence or absence of 0.75mg/ml of 
AGP. In the absence of AGP, the wound was 84% reconstituted by 24h, whereas 
in presence of AGP there was only 40% reconstitution. Therefore, AGP inhibited 
wound healing by 44%. At 24h, a wash out experiment was performed in which 
AGP was removed and cells were allowed to continue to heal. The wound reached 
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a 60% healing 12h after the AGP was removed and totally healed by 24h.  These 
data indicate the inhibitory effect of AGP at 0.75mg/ml over 24h was reversible 
and excludes irreversible loss of viability. 
 
 
 
Figure4.AGP Inhibits EC Migration in a Wounding Assay:  Wounded EC monolayers were 
cultured for 24h in the presence of AGP 0.75mg/ml or media alone and photomicrographies were 
obtained at 0h, 5h and 24h. At 24h, wash-out experiments were performed in which all wounded 
monolayers were cultured in medium alone and photomicrographes were again obtained at 36h 
and 48h. t0h was taken as 0% migration for each wound. %migration mean (+/- SE) is shown. * 
indicates significantly decreased (p<0.05) migration compared to the simultaneous media controls. 
Amount of migration was quantified from the photomicrographes using GIMP (GIMP 
development).  
 
 
AGP Influences EC Motility: Since AGP influences EC adhesion to the 
underlying ECM (matrigel) (Figure 3), EC tube formation (Figure 2) and 
migration in the wound healing assay (Figure 4), we asked whether this same 
protein might also regulate EC chemotaxis. In a modified Boyden chamber, AGP 
was introduced into either the upper or lower compartments, in the presence or 
absence of a chemotactic gradient provided by FBS in the lower compartment, 
and EC migration through the pores in the membrane filter assayed (Figure 5).  
When FBS was placed in the lower compartment we obtained a +32% migration, 
since FBS is known to be a chemoattractant. Since AGP is known to bind and 
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neutralize multiple endogenous mediators (Israili 2001), we tested FBS 
chemotactic activity in the presence and absence of AGP and we couldn’t see any 
influence of AGP in the migration behavior when FBS was present whether we 
tested AGP as a chemoattractant or a chemokinetic. Indicating thus that AGP if 
AGP binds LPS it does not dampen its chemotactic activity against EC. When 
AGP was tested alone, without the presence of FBS, it increased EC chemotaxis 
in both cases, by an 8% when it was used on the top chamber, and by a 25% when 
it was used as a chemoattractant in the down chamber being this result comparable 
to the 32% migration obtained by 0.5% LPS. These combined data indicate that 
AGP directly enhances EC motility as well as displays intrinsic chemotactic 
activity. 
 
 
 
Figure5. AGP Influences EC Motility: EC were seeded at 5x104 cells/chamber in the upper 
compartments of modified Boyden chambers in presence or absence of 0.5%FBS used as a 
positive chemoattractant control and/or the presence or absence of 0.75mg/ml AGP in the upper or 
bottom compartments. Results are expressed in fold migration using the non treated cells with no 
chemoattractant (media/media) as 1. Each bar represents mean (+/- SE) fold migration. * indicates 
significantly increased compared to the simultaneous medium controls at p<0.05. 
  
AGP Inhibits PMN Adhesion to the Endothelium: AGP is highly sialylated and 
contains selectin-like carbohydrate moieties (Shiyan 1997). We asked whether 
AGP might modify adhesive interactions between PMNs and the endothelial 
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surface. Resting and stimulated PMNs were incubated with resting or activated 
endothelial monolayers and PMN-to-endothelium adhesion quantified (Figure 6). 
AGP increased adhesion of unstimulated PMNs to resting endothelia by 52%. In 
those experiments in which only endothelia was preactivated, AGP did not alter 
PMN-to-endothelium adhesion compared to the simultaneous control. In those 
experiments where PMNs were prestimulated in the presence of absence of 
endothelial preactivation, AGP diminished PMN-to-EC adhesion by 51% and 
43%, respectively. The maximal inhibitory effect of AGP on PMN-to-
endothelium adhesion (43%inhibition) was evident after both PMNs and 
endothelia were prestimulated. These data suggest that the ability of AGP to 
disrupt PMN-to-endothelium adhesion requires surface expression of adhesion 
molecules on PMNs that are only accessible after stimulation. Prestimulation of 
EC did not appear to be critical. Protein controls using BSA (Sigma) were 
performed to rule out any protein effect (data not shown).  
 
 
Figure6. AGP Inhibits PMN Adhesion to the Endothelium:  Calcein AM-labeled PMN’s 
stimulated with fMLP/CytoB or suspended in medium alone were incubated for 30min with 
resting or LPS-activated HMVEC-L monolayers in the presence (cross-hatched bars) or absence 
(closed bars) of AGP 0.75mg/ml. After washing, fluorescence of PMNs adherent to the HMVEC-
L monolayers was measured. Each bar represents mean (+/- SE) % PMN adhesion (i.e Adherent 
PMNs/Total PMNs * 100%). * indicates significantly increased compared to the simultaneous 
medium control at p<0.05. ** indicates significantly decreased compared to the simultaneous 
medium control at p<0.05. 
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Discussion and Conclusions 
 
AGP profoundly reduced capillary-like tube formation in a HMVEC-L system 
(fig.2). The presence of increasing AGP concentrations, altered HMVEC-L 
adhesion to matrigel in a biphasic manner (fig.3). AGP increased adhesion 
(+24.5%) of HMVEC-Ls at low concentrations (0.10mg/ml and 0.25mb/ml) 
whereas high concentrations of AGP (0.75mg/ml and 1mg/ml) were inhibitory (-
29.7%). HVMEC-L migration in a wounding assay was reversibly inhibited 
(fig.4). Over 24h, AGP inhibited the migration into the wound bye 44%. 
However, removal of AGP from the media permitted HMVEC-Ls to initiate 
migration into the wound reconstituting 60% of the wound by 12h, and 100% of 
the wound by 24h (fig.4). Serum induced HMVEC-L chemotaxis in a modified 
Boyden chamber was also influenced by 0.75mg/ml AGP, when AGP was used as 
a chemoattractant we saw a 25% migration, comparable to the 32% migration we 
obtained using FBS as a chemoattractant (fig.5). When AGP was used on the 
upper compartment, as a chemokinetic, migration increased by an 8%. When AGP 
was tested in the presence of FBS, we saw no difference whether AGP was tested 
in the upper or bottom chamber. When tested for PMN adhesion, AGP gave 
different results depending on PMN activation by fMLP/CytoB or not (fig.6). 
When neutrophils were not stimulated, adhesion was  ~60% whether the 
endothelium was LPS activated or not, in presence of AGP. However, when the 
endothelium was activated, PMN adhesion diminished by ~50% in both activated 
endothelium and non. So again here, AGP seems to have a biphasic effect, 
increasing PMN adhesion of non stimulated PMNs and decreasing it when the 
neutrophils are activated independently of the LPS endothelial activation or not. 
 
Angiogenesis is a key component of normal physiological process such as 
embryonic development, endometrial proliferation and wound healing (Brooks 
1996). However, many pathological processes are also characterized by abnormal 
vascular development including arthritis, diabetic retinopathy and tumor growth 
and metastasis. We asked whether the APP, AGP, influenced new vessel 
formation. In our studies, AGP clearly inhibited Matrigel-induced angiogenesis of 
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HMVEC-Ls (fig.2). Irmak et al. performed both in vitro and in vivo angiogenesis 
assays using collagen I as a upport and VEGF-A as an angiogenesis inducer 
(Irmak, Oliveira-Ferrer et al. 2009). They found that very low concentrations of 
AGP (300ng/ml) did not exert a pro-angiogenic effect. However, they found that 
AGP synergistically works with VEGF-A to increase angiogenesis. This study is 
not in conflict with our findings since in our experiments angiogenesis was 
promoted on Matrigel, in the absence of VEGF-A and the concentrations of AGP 
were substantially higher within the range concentration found in human serum 
during physiologic conditions. 
Since in vitro angiogenesis is a multi-step process that includes adhesion to the 
underlying substrate, migration , proliferation and survival. Accordingly, we 
studied each step separately to establish whether one or mor of them was 
influenced by AGP. 
 
Matrigel is a gelatinous protein mixture secreted by Engelbreth-Holm-swarm 
mouse sarcoma cells that is mainly composed of collagen type IV, laminin and 
fibronectin (Arnaoutova, George et al. 2009). It resembles the complex 
extracellular environment found in many tissues. Endothelial cells bind to the 
extracellular matrix (ECM) through integrins (Giancotti 1999). Most integrins 
recognize multiple ECM proteins and conversely, individual matrix proteins bind 
to multiple integrins. Integrins α1β1 and α2β1 bind to collagens I, IV and laminin, 
whereas α3β1 binds mainly to laminin and fibronectin (Polverini 1996). AGP had 
a biphasic effect on adhesion, promoting it at low concentrations 0.10-0.25mg/ml 
and inhibiting it at higher ones 0.75mg/ml (fig.3). Additional studies on the 
effects of AGP on each HMVEC-L-expressed integrin are required to gain 
additional insight into the impact of AGP on the adhesion process. 
On the wounding assay, AGP inhibited the migration (fig.4). When AGP was 
removed from the media cells started migrating into the wound, reaching a 100% 
confluence 24h after the AGP wash out was performed. Asserting both that the 
AGP effect was reversible, and that the AGP concentration used, 0.75mg/ml, did 
not damage the cells. We also performed viability tests that supported this latter 
statement (data not shown). On this wounding assay, HMVEC-Ls had to detach 
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from the neighbouring cells in the monolayer before they could start migrating 
into the wound.  
To test the migration of single cells we performed a chemotaxis motility test. In 
this chemotaxis assay (fig.5), single cell suspensions were incubated in modified 
Boyden chambers where migration across a pourous membrane was quantified. 
When FBS was used as a chemoattractant in the bottom chamber, no changes in 
migration were observed in presence of AGP, whether this was incubated in the 
upper or bottom compartment. AGP is known to bind and transport over 300 
molecules (Israili and Dayton 2001), so we tested AGP alone, without the 
presence of FBS to see if FBS was interfering in AGP’s activity. In this case we 
saw a slight chemokinetic activity when AGP was incubate in the upper chamber 
and a clear chemotaxis activity compearble to that exhert by LPS alone. This 
results support Irmak’s paper were they report an increased endothelial cell 
migration even at very low AGP concentrations (5ng/ml-300ng/ml) (Irmak, 
Oliveira-Ferrer et al. 2009). This findings might be explained by the fact that 
during an acute phase response, new vessels might be needed to support he 
damaged tissue, and thus AGP acts as a chemotactic factor. 
 
On the last set of experiments, AGP diminished adhesion of fMLP activated 
PMN’s to the endothelium independently of it being LPS-activated or not. 
Activated PMNs bind to  the endothelium mainly PSGL1, L-Selectin and 
glycosylated molecules that bind to E-Selectin, PSGL1 binds to P-Selectin 
through the terminal Sialyl LewisX (sLex) and L-Selectin binds to the sialylated 
ligands on the endothelium. AGP has a high carbohydrate content that has a high 
affinity for E-selectin thus blocking this receptors for the PMNs to bind to (Lasky 
1992). Plus the highly fucosylated and sialylated forms of AGP could compete 
with endothelial receptors in the adhesion process of the PMNs by blocking the L-
selectin and the PSGL1 on the activated neutrophil. 
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 FINAL REMARKS 
 
• Exogenous plasma boAGP binds to bovine neutrophils surface in an 
homogeneous way. 
• High concentrations of boAGP down-regulate both spontaneous and ZAS 
induced exocytosis of secondary granules in bovine PMNs. 
• When AGP is desialylated,  the down-regulation activity is lost. 
• Capillary-like tube formation of HMVEC-Ls on Matrigel is inhibited by 
hAGP. 
• hAGP regulates HMVEC-L adhesion to Matrigel in a biphasic manner. 
• Wound healing of HMVEC-Ls is inhibited by hAGP  in a reversible 
manner. 
• hAGP acts as a chemoattractant, in modified Boyden chambers for 
HMVEC-Ls. 
• hAGP diminishes, PMN adhesion to endothelium when those are 
fMLP/CytoB activated. 
 
 
FUTURE DIRECTIONS 
 
• In vivo studies for the angiogenesis inhibition. 
• Binding studies with different integrins to resolve the biphasic behavior on 
the Matrigel adhesion 
• Permeability assays, to see if the tightening of the monolayer is the cause 
of the wound healing inhibition since the chemotactic activity has already 
been proven. 
• Further studies on human PMNs need to be done in order to fully 
understand the diminished adhesion. 
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